| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 12/06/2001 | WO2001046225A3 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 12/06/2001 | WO2001046224A3 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 12/06/2001 | WO2001041704A3 Method for the prevention and/or treatment of atherosclerosis |
| 12/06/2001 | WO2001034646A3 Recombinant gelatins |
| 12/06/2001 | WO2001034130A9 Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| 12/06/2001 | WO2001030381A3 Use of csf-1 inhibitors |
| 12/06/2001 | WO2001023421B1 Stress protein compositions and methods for prevention and treatment of cancer and infectious disease |
| 12/06/2001 | WO2001016345A3 Sequence-specific dna recombination in eukaryotic cells |
| 12/06/2001 | WO2001014416A3 Synthetic papillomavirus genes optimized for expression in human cells |
| 12/06/2001 | WO2001012775A8 25 human secreted proteins |
| 12/06/2001 | WO2001005432A3 Conjugate for mediating cell, compartment or membrane-specific transport of active substances |
| 12/06/2001 | WO2000077233A3 Complement-resistant non-mammalian dna viruses and uses thereof |
| 12/06/2001 | WO2000038517A9 Methods for reducing adverse side effects associated with cellular transplantation |
| 12/06/2001 | WO2000025804A9 A method for inhibition of phospholamban activity for the treatment of cardiac disease and heart failure |
| 12/06/2001 | US20010049360 Betaglycan as an inhibin receptor and uses thereof |
| 12/06/2001 | US20010049355 Providing exogenous SLED to endothelial cells; maybe be provided systemically, topically, or via a vector comprising a SLED expression cassette |
| 12/06/2001 | US20010049145 Hepatitis B virus vectors for gene therapy |
| 12/06/2001 | US20010049144 Genetically engineering a primate for expression of a desired gene, comprising introducing into the primate a transgene of a Rous Sarcoma Virus promoter (RSV) and a nucleic acid sequence heterologous to said RSV promoter; gene therapy |
| 12/06/2001 | US20010049136 Deletion of: all or part of the E1A regions, the E1B region coding for the early proteins, E2 or E4 regions, the E1a region and encapsidation region; gene therapy |
| 12/06/2001 | US20010049121 Polypeptides and polynucleotides; drug screening, use in therapy, diagnostic assays |
| 12/06/2001 | US20010049106 ADAM (A Disintegrin And Metalloprotease) family of metalloproteases, and in addition contain thrombospondin domain (TS); treating diabetes, arthritis, cancer, solid tumors, autoimmune diseases |
| 12/06/2001 | US20010048940 Supplying genes into mammal cells |
| 12/06/2001 | US20010048939 Cationic reagents of transfection |
| 12/06/2001 | US20010048919 Virus clearance of neoplastic cells from mixed cellular compositions |
| 12/06/2001 | DE10025920A1 Verfahren und Mittel zur Behandlung von Immunreaktionen am Auge Method and agent for the treatment of immune responses in the eye |
| 12/06/2001 | CA2414017A1 Inhibiting retrotransposon and retroviral integration by targeting the atm pathway |
| 12/06/2001 | CA2413995A1 Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity |
| 12/06/2001 | CA2411040A1 Therapeutic anti-melanoma compounds |
| 12/06/2001 | CA2410981A1 Adenovirus particles with mutagenized fiber proteins |
| 12/06/2001 | CA2410949A1 Novel target genes for diseases of the heart |
| 12/06/2001 | CA2410947A1 Methods for mediating gene suppresion by using factors that enhance rnai |
| 12/06/2001 | CA2410903A1 Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy |
| 12/06/2001 | CA2410895A1 Therapeutic compounds for ovarian cancer |
| 12/06/2001 | CA2410865A1 Therapeutic compounds for ovarian cancer |
| 12/06/2001 | CA2410758A1 Use of acrp30 globular head to promote increases in muscle mass and muscle differentiation |
| 12/06/2001 | CA2410665A1 Modified bovine adenovirus having altered tropism |
| 12/06/2001 | CA2410523A1 Targeted chromosomal genomic alterations in plants using modified single stranded oligonucleotides |
| 12/06/2001 | CA2410516A1 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 12/06/2001 | CA2410515A1 Method of identifying and/or isolating stem cells |
| 12/06/2001 | CA2410514A1 Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways |
| 12/06/2001 | CA2410489A1 Human kcnq5 potassium channel, methods and compositions thereof |
| 12/06/2001 | CA2410480A1 Reagents and methods for identifying and modulating expression of genes regulated by retinoids |
| 12/06/2001 | CA2410436A1 Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| 12/06/2001 | CA2410419A1 Improved methods of transfection |
| 12/06/2001 | CA2410265A1 Lyophilizable and enhanced compacted nucleic acids |
| 12/06/2001 | CA2410015A1 Methods of transducing neural cells using lentivirus vectors |
| 12/06/2001 | CA2409932A1 Combination of a mutant herpes virus and a chemotherapeutic agent for the treatment of cancer |
| 12/06/2001 | CA2401974A1 Dna expression vectors and methods of use |
| 12/05/2001 | EP1160323A1 5T4 tumour-associated antigen for use in tumour immunotherapy |
| 12/05/2001 | EP1160321A1 Kidney Injury Novel Gene-1: Isolation and therapeutic applications |
| 12/05/2001 | EP1160320A1 Use of hTAFII80 and isoforms thereof for inducing apoptosis |
| 12/05/2001 | EP1160318A2 Medicament for treatment of Duchenne muscular dystrophy |
| 12/05/2001 | EP1159455A2 cDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE |
| 12/05/2001 | EP1159439A2 Enhanced system for construction of adenovirus vectors |
| 12/05/2001 | EP1159438A1 Means and methods for fibroblast-like or macrophage-like cell transduction |
| 12/05/2001 | EP1159437A2 Method to improve translation of polypeptides by using untranslated regions from heat-shock proteins |
| 12/05/2001 | EP1159433A1 Translation regulation system and methods for use thereof |
| 12/05/2001 | EP1159431A2 Human kallikrein-like genes |
| 12/05/2001 | EP1159423A2 Uses of transgenic animals containing a type x collagen mutant |
| 12/05/2001 | EP1159422A1 Compositions and methods for the treatment of tumors |
| 12/05/2001 | EP1159420A1 Human pancreas and pancreatic cancer associated gene sequences and polypeptides |
| 12/05/2001 | EP1159419A1 Promotion or inhibition of angiogenesis and cardiovascularization |
| 12/05/2001 | EP1159418A2 Muc-1 antagonists and methods of treating immune disorders |
| 12/05/2001 | EP1159417A2 Polynucleotides and proteins encoded thereby |
| 12/05/2001 | EP1159415A2 Genetic modification of somatic cells and uses thereof |
| 12/05/2001 | EP1159414A1 Process for enhancing electric field-mediated delivery of biological materials into cells |
| 12/05/2001 | EP1159412A2 Composition, methods and reagents for the synthesis of a soluble form of human phex |
| 12/05/2001 | EP1159409A1 Introducing a biological material into a patient |
| 12/05/2001 | EP1159408A2 Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof |
| 12/05/2001 | EP1159406A2 Human glycosylation enzymes |
| 12/05/2001 | EP1159287A1 50 human secreted proteins |
| 12/05/2001 | EP1159286A1 Tumor necrosis factor receptors 6 alpha and 6 beta |
| 12/05/2001 | EP1159284A1 33 human secreted proteins |
| 12/05/2001 | EP1159012A1 Encapsulated cells containing an amplified expression vector as a drug delivery device |
| 12/05/2001 | EP1159000A2 Preparation for the treatment of pigmentation disorders |
| 12/05/2001 | EP1158999A2 Methods for improving graft acceptance in a recipient by administration of a cytokine profile altering agent |
| 12/05/2001 | EP1158998A1 Cardiac muscle function and manipulation |
| 12/05/2001 | EP1158966A1 Bacterial ghosts as carrier and targeting vehicles |
| 12/05/2001 | EP1158856A1 Human fas |
| 12/05/2001 | EP0955999B1 Novel liposome complexes for increased systemic delivery |
| 12/05/2001 | EP0904282B1 Novel cationic cholesteryl derivatives containing cyclic polar groups |
| 12/05/2001 | EP0692972B1 Method for delivering beneficial compositions to hair follicles |
| 12/05/2001 | CN1325451A Recombinant adevovirus for tissue specific expression in heart |
| 12/05/2001 | CN1325450A Adenovirus-mediated gene therapy |
| 12/05/2001 | CN1325407A Platelet-derived growth factor D, DNA coding therefor and uses thereof |
| 12/04/2001 | US6326483 Nucleotide sequences which code protein associated with tumor suppression; for diagnosis and treatment of cell proliferation disorders |
| 12/04/2001 | US6326465 Immunomodulatory polypeptides derived from the invariant chain of MHC class II |
| 12/04/2001 | US6326464 Genetically engineered tumor suppressor protein; for use in the treatment of cancers; antiproliferative agents |
| 12/04/2001 | US6326356 Antitumor agents |
| 12/04/2001 | US6326354 Modulation of apoptosis with bid |
| 12/04/2001 | US6326205 Methods for use of Mpl ligands with primitive human stem cells |
| 12/04/2001 | US6326199 Hybridization and rnace activation in a cell with oligonucleotides |
| 12/04/2001 | US6326198 Generating human stem cell propagation; inoculate solution with, human hematopoietic stem cells in presence of human bone marrow stromal cells, culture, recover cells |
| 12/04/2001 | US6326195 Recombinant retroviral vector |
| 12/04/2001 | US6326172 ytgP |
| 12/04/2001 | US6326170 Prokaryotic polynucleotides, polypeptides and their uses |
| 12/04/2001 | US6326152 Exposing nadh dehydrogenase-expressing cells to test compound; measuring expression or enzymatic activity of nadh dehydrogenase in cells; selecting compound that down-regulates nadh dehydrogenase expression or activity |
| 12/04/2001 | US6326141 Detecting pancreatic defect; evaluate humans for preferential gene expression, compare to healty human, amplified expression from preferential gene indicates pancreatic defect |
| 12/04/2001 | US6326007 Genes responsible for pathogenesis completely or partially nonfunctional by modifying or deleting nef (negative effector) start codon; enhanced expression of cytokine and/or lymphokine; vaccines |
| 12/04/2001 | US6325999 Use of Fas ligand to suppress T-lymphocyte-mediated immune responses |